Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9307815 | 0.87 | MEN1 (0.31) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL11500450 | 0.86 | MEN1 (0.33) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL1033008 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL51201 | 0.78 | FFAR3 (0.41) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Methane SCHEMBL28218821 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL22283924 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL16054795 | 0.77 | ALDH1A1 (0.37) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL10875807 | 0.76 | MEN1 (0.31) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| Carbon Tetrachloride SCHEMBL10421671 | 0.76 | ALDH1A1 (0.42) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL9489101 | 0.75 | FFAR3 (0.39) | ALDH1A1MEN1CYP1A2THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | disclosed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1863500-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060234963-A1 | Hepatitis C therapies | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2006-10-19 | — | — | US | disclosed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078218-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | ALDH1A1 435/4885MEN1 4715/4885CYP1A2 982/4885 |
| US-20060234963-A1 | Hepatitis C therapies | HAVCR2, FABP1, LIPC | ALDH1A1 435/4885MEN1 4715/4885CYP1A2 982/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | ALDH1A1 435/4885MEN1 4715/4885CYP1A2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.